Fig. 1: Identification and detection of milRNAs of SARS-CoV-2 in the sera from COVID-19 patients. | Cell Discovery

Fig. 1: Identification and detection of milRNAs of SARS-CoV-2 in the sera from COVID-19 patients.

From: A virus-derived microRNA-like small RNA serves as a serum biomarker to prioritize the COVID-19 patients at high risk of developing severe disease

Fig. 1

a Overview of the study design. b SARS-CoV-2-derived small RNAs in the sera of COVID-19 patients and healthy controls. c Genomic position and stem-loop structure of the precursor of miR-nsp3-3p. Mature miR-nsp3-3p is indicated in red. d The individual CT values of miR-nsp3-3p in the serum from severe patients, mild/moderate patients, and healthy controls in the validation cohorts 1, 2, and 3. Serum samples were collected from mild/moderate patients who remained at a mild or moderate condition or from severe patients who had developed a severe or critically severe illness. The lower boundary of the detection spectrum of each cohort is indicated by a dotted line. e The absolute concentrations of miR-nsp3-3p in the serum from validation and testing cohorts. In testing cohort, serum samples were collected from mild/moderate patients at the time of admission and before discharge or from severe patients when the disease progressed from pre-severe stage (before manifestation of severe symptoms) to severe stage and then to recovery stage. f The cumulative accuracy rate of miR-nsp3-3p, D-dimer, CRP, LDH, and PLC in predicting the risk of critical illness and monitoring disease progression.

Back to article page